Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
1995-9-11
pubmed:abstractText
With a median observation time of 50 months from transplant, 13 (22%) of 62 women with metastatic breast cancer treated with high-dose chemotherapy at the Dana-Farber Cancer Institute (DFCI)/Beth Israel Hospital (BIH) remain progression-free. This study determined factors prognostic for prolonged progression-free survival (PFS).
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2043-9
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:7636547-Adolescent, pubmed-meshheading:7636547-Adult, pubmed-meshheading:7636547-Age Factors, pubmed-meshheading:7636547-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:7636547-Bone Marrow Transplantation, pubmed-meshheading:7636547-Breast Neoplasms, pubmed-meshheading:7636547-Carboplatin, pubmed-meshheading:7636547-Combined Modality Therapy, pubmed-meshheading:7636547-Cyclophosphamide, pubmed-meshheading:7636547-Disease-Free Survival, pubmed-meshheading:7636547-Female, pubmed-meshheading:7636547-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:7636547-Humans, pubmed-meshheading:7636547-Middle Aged, pubmed-meshheading:7636547-Multivariate Analysis, pubmed-meshheading:7636547-Neoplasm Metastasis, pubmed-meshheading:7636547-Prognosis, pubmed-meshheading:7636547-Proportional Hazards Models, pubmed-meshheading:7636547-Remission Induction, pubmed-meshheading:7636547-Thiotepa, pubmed-meshheading:7636547-Transplantation, Autologous
pubmed:year
1995
pubmed:articleTitle
Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer.
pubmed:affiliation
Dana-Farber Cancer Institute, Beth Israel Hospital, Harvard Medical School, Boston, MA, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't